← All reports

Soligenix's HyBryte treatment for cutaneous T-cell lymphoma has demonstrated safety and efficacy based on peer-reviewed clinical data.

HealthcareTechnologyMay 16, 2026score 0.172 posts · 0 replies across 1 instances
Soligenix shares positive clinical trial results for its HyBryte treatment for cutaneous T-cell lymphoma, with potential to accelerate commercialization. The data is peer-reviewed and expected to be released in Q2 2026.

Claims

Soligenix's HyBryte treatment for cutaneous T-cell lymphoma has demonstrated safety and efficacy based on peer-reviewed clinical data.
Parent: BiotechnologyEntity: SoligenixSub-entity: HyBryteImpact: positiveDate: May 16, 2026Target: Soligenix's HyBryte treatment for cutaneous T-cell lymphoma has demonstrated safety and efficacy based on peer-reviewed clinical data.

Source posts

@[email protected]
Soligenix publishes peer-reviewed HyBryte clinical data demonstrating safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 trial interim results expected Q2 2026. #Biotech #RareDiseases
0 boosts · 0 favs · 0 replies · May 16, 2026
#biotech#rarediseases
@[email protected]
Soligenix reports strong Phase 3 HyBryte data for cutaneous T-cell lymphoma, with response rates exceeding expectations. Interim analysis could accelerate commercialization path. #Biotech #RareDiseases
0 boosts · 0 favs · 0 replies · May 16, 2026
#biotech#rarediseases